OasisLMS

This Cerebrovascular session was recorded live at the 2025 AANS Annual Scientific Meeting.

The treatment of cerebrovascular disease is married to diagnostic and therapeutic techology and techniques. This session will feature evolutions and novel developments in the management of cerebral vascular pathology.

Speakers: Mostafa Abdulrahim, Sepideh Amin-Hanjani, Adam Arthur, Abdessamad El Ouahabi, Christopher Kellner, Mika Niemela, Wei Ni, Vita Olson, Zeynep Ozdemir, Felipe Ramirez Velandia, Georgios Sioutas, Stavropoula Tjoumakaris

The AANS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AANS designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The last date to claim credit is 06/26/2027.

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the AANS must ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Education, the AANS is required to disclose to the activity audience the relevant financial relationships of the planners, faculty and any other individual in a position to control content of this activity.

Those who have disclosed a relationship with ineligible companies are listed below.

All disclosed financial relationships have been mitigated in accordance with ACCME standards.

Name	Relationship/Company
Adam Arthur, MD	Arsenal Medical: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Balt: Consultant (Ongoing), Grant/Research Support (Ongoing); Bend IT Technologies, Ltd.: Stock Shareholder (excluding mutual funds) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); Medtronic: Consultant (Ongoing), Grant/Research Support (Ongoing); Microvention: Consultant (Ongoing), Grant/Research Support (Ongoing); Neuros Medical: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Nuvascular: Consultant (Ongoing); NVMedtech: Consultant (Ongoing); Penumbra: Consultant (Ongoing), Grant/Research Support (Ongoing); Perfuze: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); RevBio: Stock Shareholder (excluding mutual funds) (Ongoing); Scientia: Consultant (Ongoing); Serenity Medical, Inc: Stock Shareholder (excluding mutual funds) (Ongoing); Siemens: Consultant (Ongoing), Grant/Research Support (Ongoing); Stryker: Consultant (Ongoing), Grant/Research Support (Ongoing); Synchron Inc: Stock Shareholder (excluding mutual funds) (Ongoing); Tulavi Therapeutics, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Vastrax, LLC: Stock Shareholder (excluding mutual funds) (Ongoing)
Stavropoula Tjoumakaris, MD	Medtronic Inc: Consultant (Ongoing)

Planners, faculty and any other individuals in control of content not listed have indicated that they have no relevant financial relationships or conflict of interest to disclose for this activity.